Can Ozempic Help You Quit Smoking? What the Trials Actually Show

You've probably heard some version of this story by now. Someone starts Ozempic or Wegovy for their weight, the food noise goes quiet, and then they notice something they weren't expecting — they don't want their afternoon cigarette either. The shot that turned down the volume on hunger seems to have turned it down on smoking too.

It's a great story. The only question that matters is whether it survives contact with the trial data.

Here's the honest version, because it isn't a clean yes or no. For quitting smoking itself, the evidence is thin, and the best-designed test so far came up empty. For the thing smokers actually dread — the weight that piles on after you quit — there's a real, if modest, signal. Those are two different findings. Most of the hype smashes them into one, and the rest of this piece is about keeping them apart.

The "it kills every craving" theory, and where it comes from

The appeal makes intuitive sense. If a drug can dampen the pull of food, maybe it dampens other pulls too. Nicotine, after all, hits some of the same reward machinery in the brain that a slice of cake does.

GLP-1 receptor agonists — the class that includes semaglutide, sold as Ozempic for type 2 diabetes and Wegovy for obesity — were never designed with cigarettes in mind. They mimic a gut hormone that tells your brain you're full. But those same receptors show up in brain regions tied to reward and craving, not just appetite. That overlap is the entire reason anyone thought to test the idea.

And the lived experience kept showing up, unprompted. People on these drugs report that their interest in alcohol drops, that compulsive snacking eases, that the cigarette they used to reach for feels less urgent. When enough people volunteer the same odd observation, researchers stop waving it away and start designing trials. Which is exactly what happened here.

Why the question won't go away — reward circuits and the fear of post-quit pounds

Two forces drive the curiosity, and they pull in opposite directions.

The first is mechanistic hope. Addiction, whether to food or nicotine, runs partly through shared dopamine pathways. If a medication can blunt one craving, it's not unreasonable to wonder whether it blunts the next. That's a hypothesis worth testing, not a conclusion you get to assume.

The second is more practical — and honestly, more important to most smokers than the first. A huge reason people put off quitting, or relapse after they've managed it, is the weight that tends to follow. The cigarettes go, the appetite returns, the scale climbs, and that becomes the excuse to light up again. If a GLP-1 could hold that weight in check through the hardest months, it might erase one of the biggest reasons people give for not even trying.

Hold onto that second point. It's where the data turns out to be kindest.

What the semaglutide trial actually measured

Semaglutide first, because it's the molecule behind the famous names and the one most people are picturing when they ask this question.

A phase 2a randomized controlled trial put it to the test. The setup was small by design — a phase 2a study is an early, proof-of-concept look, not a definitive verdict. Of 45 participants enrolled, 24 were randomized. Tiny numbers, and worth keeping in mind before you read too much into the result.

The result, stated plainly: semaglutide on its own did not significantly reduce the number of cigarettes smoked per day, and it didn't significantly increase smoking resistance in the lab. The primary outcome — the thing the trial was built to detect — came back null. If you walked in hoping the headline would read "Ozempic helps you smoke less," that is not what this trial found.

Semaglutide failed its primary smoking outcome. It did not meaningfully cut daily cigarettes. Any claim that the data "proves" it helps you quit is reading something into a null result that isn't there.

But two secondary findings did move, and that's where the nuance lives. Nicotine craving went down. So did body weight. Neither of those is the same as quitting, and a phase 2a trial this small can't carry much on its own. Still, it's a clue about which way the real effect might point — not at whether you stub out the cigarette, but at the craving and the weight wrapped around it.

Exenatide plus a patch: a signal, not a verdict

The next study looks more encouraging on the surface, which is exactly why it needs careful handling.

Exenatide is an older GLP-1 drug, used for type 2 diabetes and sold under brand names you're less likely to recognize. In a pilot trial, researchers paired it with a nicotine patch — the patch alone being a standard quit aid — and compared that against the patch plus a placebo. On paper, the exenatide group did better.

At end-of-treatment, 46.3% of the exenatide group had quit, versus 26.8% in the placebo group. On its face that's a striking gap, nearly twice the quit rate. You can see why a number like that travels fast.

Now the part that travels slower and matters more. This was a pilot study, which means it was small and built to explore feasibility, not to settle anything. The difference between those two quit rates was not statistically significant — meaning the gap could plausibly be chance rather than a true drug effect. A promising signal, yes. Proof, no. Those words mean different things, and a pilot trial earns you only the first.

The weight piece pointed the same direction it did with semaglutide. Over 6 weeks, the exenatide group's post-quit weight drifted down by about 0.49 lb, while the placebo group's climbed by 2.96 lb. Small study, short window — but the pattern holds: the GLP-1 seemed to blunt the post-cessation weight gain even when the quitting itself was a coin toss.

Dulaglutide is the one that settles it

The dulaglutide trial is the most useful of the three, precisely because it's the most deflating about quitting and the most honest about weight.

Dulaglutide is another GLP-1 used for type 2 diabetes. This randomized controlled trial was larger and cleaner than the others, and it asked the direct question: does adding dulaglutide help people quit? After 12 weeks, 63% of the dulaglutide group were abstinent. In the placebo group, 65% were. Those two numbers are, for all practical purposes, identical. On quitting, dulaglutide did nothing the placebo wasn't already doing.

63% versus 65%. When the drug group quits at essentially the same rate as placebo, that's not a weak effect — it's the absence of one. On smoking cessation, this trial is a clean null.

Then the weight data, which is the whole reason to keep reading. At 12 weeks, the dulaglutide group had lost about 1 kg after quitting, while the placebo group had gained about 1.9 kg — a baseline-adjusted difference of roughly 2.9 kg. That's a meaningful split during the exact window when post-quit weight gain does its damage. People quit, the scale moves, they relapse over it — and here was a drug holding the line through the hardest stretch.

The honesty comes at the end. By week 52, the gap had closed. The dulaglutide group had gained about 2.8 kg, the placebo group about 3.1 kg, close enough to call a wash. So the weight benefit was real but temporary, bunched into the early months and fading by the one-year mark. It buys time. It doesn't rewrite the ending.

The three trials, lined up

Three studies, three different drugs, three different outcomes. Laid side by side, the pattern reads more clearly than any single trial lets on.

Now the same three studies, read through the weight lens instead:

Read across the first table and the quitting story keeps fizzling: one null, one non-significant signal, one clean null. Read across the second and a quieter, more consistent thread holds together — in every trial that measured it, the GLP-1 group's weight behaved better than placebo during the quit. Same drugs, two very different verdicts.

And here's the boundary nobody can wave away

None of this is an approved use, and that line deserves no hedging. No GLP-1 receptor agonist is approved by the FDA for smoking cessation. Not semaglutide, not exenatide, not dulaglutide. As a quit aid, the entire class sits in the investigational, off-label category — researchers are still studying whether it works, and the early answer for quitting itself is mostly "not yet, and maybe not at all."

That's not a technicality. It's the gap between a treatment your doctor can prescribe for a recognized purpose and a hypothesis still being tested in trials. The approved quit-smoking toolkit — nicotine replacement, varenicline, bupropion, counseling, the things with decades of evidence behind them — is where the real cessation help still lives. A GLP-1 isn't a member of that club, no matter how convincing the craving stories sound.

If there's a genuine signal anywhere in all this, it isn't on the cigarette. It's on the weight that tends to follow the cigarette. And even that is modest and, in the one trial that tracked it for a full year, temporary.

Already on a GLP-1? The safety basics worth knowing

Plenty of smokers are already taking one of these drugs for diabetes or weight, which is partly why the smoking question comes up at all. A few things are worth understanding about the medication itself, separate from any quit-smoking ambition.

The most common side effects are gastrointestinal. Nausea, vomiting, diarrhea, abdominal pain, and constipation lead the list, and they tend to be at their worst early on. For most people they ease with time, but they're the reason a lot of folks find the first few weeks rough.

Then there's a hard line, and it sits in a different category entirely. Several drugs in this class — semaglutide among them — carry a boxed warning, the FDA's most serious, for thyroid C-cell tumors, and they are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contraindicated means do not use, full stop. This isn't a "keep an eye on it" caution. It's absolute.

Pancreatitis sits at a different level. Acute pancreatitis has been reported in people taking these drugs, and the guidance is to stop promptly if it's suspected. That's a relative caution — a reason for vigilance and a conversation with your clinician, not the automatic disqualifier that a thyroid history is. Keeping the two straight matters: one is an absolute no, the other is a careful maybe.

None of this is a reason to start, stop, or adjust a medication on your own based on something you read. If thyroid cancer runs in your family, that's exactly the kind of history to raise with your doctor before any GLP-1 enters the picture.

So where does that leave a smoker who wants to quit?

A handful of honest takeaways, given everything above.

Don't reach for a GLP-1 as a quit-smoking drug. The evidence doesn't support it, and the strongest trial came back null. If quitting is the goal, the proven tools — nicotine replacement, prescription cessation medications, counseling, a real quit plan with a date on it — are still the answer, and they're worth a conversation with your doctor or a quitline.

If you're worried about gaining weight when you quit, you're worried about the right thing. That fear is one of the most common reasons people relapse, and it's legitimate, not vanity. The GLP-1 data is at its most interesting right here — but it's early, off-label, and in at least one trial the benefit faded inside a year. It's a research thread, not a plan you build around.

And if you already take a GLP-1 for diabetes or weight and you happen to notice the cravings feel quieter, that's worth mentioning to your doctor — not as a reason to change anything, but as a useful data point about your own response. Don't start one for smoking. Don't stop one because of smoking. Let the person who knows your history weigh in.

The unglamorous truth is that quitting still mostly comes down to the boring, effective things: a quit date, support, the approved medications, and getting through the rough stretch. A GLP-1 might one day earn a supporting role around the edges, especially on weight. It hasn't earned the lead.

What to ask at your next appointment

If any of this is rattling around in your head, here are the questions worth bringing to a clinician — framed the way they'll be useful.

Is a GLP-1 appropriate for me at all, given my health history? This is the threshold question, especially if there's any family history of thyroid cancer or MEN 2 in the picture.

If I'm already on one and I want to quit smoking, what proven cessation tools should I be using? The honest answer should point you toward the approved options, not toward the shot you're already taking.

How do I handle the weight if I quit? This is the conversation where the GLP-1 research is most relevant — but it's a discussion about your specific situation, not a license to self-prescribe a use no regulator has signed off on.

What side effects should send me back to you quickly? Knowing the difference between the early nausea that fades and the warning signs that need attention is one of the more useful things you can walk out of an appointment carrying.

Everything here is drawn from published clinical trials and the prescribing information behind these drugs, not from anyone's personal experience — so treat it as background for a conversation, and let a clinician who knows your history make the actual call about whether any medication fits.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app